Loading
AG
Applied Genetic Technologies Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Krol Patrick Johan Hendrik, was filed 26 Nov 2019.
Applied Genetic Technologies Corp: what insiders have been doing
Headquartered in Alachua, United States, Applied Genetic Technologies Corp belongs to the Healthcare & Pharma sector and traces its origins to 2001. Filings by its managers are published through SEC (Form 4). Nothing new has been filed by managers of Applied Genetic Technologies Corp in twelve months, the latest record being from 1 December 2022.
Since 2016, the database holds 13 purchases and 6 sales by insiders of the company.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
97
Thresholds
n/a
Buy Volume
€182,338
13 ops. · all time
Sell Volume
€426,763
6 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended June 2022 · cache
Income statement
RevenueUS$279.8k
Net income-US$59.4M-21213.2% margin
Last declaration on 1 December 2022
Declarations97 total
1,800 sharesCommon StockSEC:0001062993-22-023026:1
42,500 sharesCommon StockSEC:0001062993-22-023023:1
8,750 sharesCommon StockSEC:0001062993-22-023021:1
8,500 sharesCommon StockSEC:0001062993-22-023027:0
34,246 sharesCommon StockSEC:0001062993-22-023024:0
1,000 sharesCommon StockSEC:0001062993-22-023028:0
25,672 sharesCommon StockSEC:0001062993-22-023026:0
143,021 sharesCommon StockSEC:0001062993-22-023017:0
8,506 sharesCommon StockSEC:0001062993-22-023023:0
47,133 sharesCommon StockSEC:0001062993-22-023021:0
30,000 shares0Common StockSEC:0001062993-22-018740:0
8,070 shares@ US$0.774525.6% of flowCommon StockSEC:0001062993-22-015725:0
3,994 shares@ US$0.8452100.0% of flowCommon StockSEC:0001062993-22-013865:0
9,950 shares@ US$2.1817.4% of flowCommon StockSEC:0001062993-22-005202:1
120,686 shares@ US$0.3576.0% of flowCommon StockSEC:0001062993-22-005202:0
3,877 shares@ US$3.5024.0% of flowCommon StockSEC:0001273636-21-000030:0
5,724 shares@ US$3.5874.4% of flowCommon StockSEC:0001273636-21-000020:0
35,000 shares0Common StockSEC:0001273636-21-000011:0
5,723 shares@ US$5.77100.0% of flowCommon StockSEC:0001273636-20-000004:0
5,723 shares@ US$5.7754.5% of flowCommon StockSEC:0001273636-20-000005:0
81,162 shares@ US$5.2498.4% of flowCommon StockSEC:0001104659-19-076800:0
2,544 shares@ US$2.791.6% of flowCommon StockSEC:0001104659-19-067700:0
Canonical exit: 17 Feb 2020 (T+90)
5,700 shares@ US$3.5024.4% of flowCommon StockSEC:0001273636-19-000039:0
39,000 shares0Common StockSEC:0001273636-19-000034:0
39,000 shares0Common StockSEC:0001273636-19-000035:0
25 of 97 declarations
About Applied Genetic Technologies Corp
Applied Genetic Technologies Corp. (AGTC) is a United States biotech company historically listed on the NASDAQ, positioned in the healthcare and gene-therapy segment. Founded in 1999, the company emerged from academic and translational research in genetic medicine and built its strategy around a proprietary adeno-associated virus (AAV) gene-therapy platform aimed at rare inherited diseases. Its operational headquarters have been in Alachua, Florida, reflecting its roots in the Gainesville-area biotechnology cluster. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1273636/000119312522252231/d374747d10k.htm?utm_source=openai))
AGTC’s core business has centered on clinical and preclinical gene-therapy development, with an initial emphasis on ophthalmology. Public filings describe programs directed at serious rare eye diseases, including X-linked retinitis pigmentosa, achromatopsia, and X-linked retinoschisis, and also show the company expanding its research footprint into other rare-disease areas over time. The strategic logic is straightforward: target monogenic conditions with clear biology, high unmet medical need, and the potential for durable benefit if a gene therapy can successfully deliver functional genetic material to the relevant tissue. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1273636/000119312522252231/d374747d10k.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, AGTC operated in a highly specialized, capital-intensive part of biotech. In gene therapy, competition comes from other platform developers and clinical-stage companies rather than from traditional pharma alone. Differentiation depends on vector design, transgene expression, tissue targeting, manufacturing know-how, and clinical execution. AGTC’s positioning was built on its AAV expertise, intellectual property, and collaborations with external scientific partners, all of which were meant to support development in niche ophthalmic and other orphan indications. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1273636/000119312522252231/d374747d10k.htm?utm_source=openai))
The company should be viewed more as a development-stage asset than a commercial product business. Its value proposition historically came from the pipeline, research capabilities, licensing activity, and collaboration agreements rather than from large-scale product sales. SEC disclosures note that AGTC had not generated product revenue and depended on external financing and continued R&D progress to advance its candidates. For investors, that means the equity story is driven by clinical milestones, regulatory progress, partnership potential, and cash runway rather than stable operating earnings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1273636/000119312522252231/d374747d10k.htm?utm_source=openai))
Recent market context also matters. The company has been followed for SEC reporting activity, including Form 4 insider transactions, which can be relevant for small-cap biotech investors assessing insider sentiment and governance transparency. In practical terms, AGTC fits the profile of a U.S.-listed NASDAQ biotech: scientifically focused, milestone-driven, and highly sensitive to clinical data, financing conditions, and regulatory developments. For French-speaking investors in France, Belgium, or Switzerland, the key takeaway is that AGTC is a speculative gene-therapy name with a rare-disease focus, a Florida base, and a long-duration risk/reward profile typical of early-stage biotechnology. ([secform4.com](https://www.secform4.com/insider-holders/1273636.html?utm_source=openai))
